Viridian Therapeutics, Inc. $VRDN is Eversept Partners LP’s 7th Largest Position

Eversept Partners LP lessened its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 7.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,782,235 shares of the company’s stock after selling 142,071 shares during the period. Viridian Therapeutics makes up 2.8% of Eversept Partners LP’s portfolio, making the stock its 7th biggest position. Eversept Partners LP’s holdings in Viridian Therapeutics were worth $55,463,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in VRDN. Morgan Stanley grew its position in Viridian Therapeutics by 805.6% during the fourth quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock valued at $54,094,000 after acquiring an additional 1,546,284 shares during the period. Avoro Capital Advisors LLC purchased a new stake in Viridian Therapeutics during the fourth quarter valued at about $46,680,000. Vanguard Group Inc. lifted its stake in shares of Viridian Therapeutics by 29.6% during the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock worth $174,650,000 after purchasing an additional 1,280,161 shares in the last quarter. Commodore Capital LP lifted its stake in shares of Viridian Therapeutics by 35.4% during the second quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after purchasing an additional 1,275,000 shares in the last quarter. Finally, Jennison Associates LLC acquired a new position in shares of Viridian Therapeutics during the fourth quarter worth about $35,915,000.

Viridian Therapeutics Trading Up 4.6%

NASDAQ:VRDN opened at $16.71 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15. Viridian Therapeutics, Inc. has a one year low of $13.18 and a one year high of $34.29. The business’s 50-day simple moving average is $15.91 and its 200 day simple moving average is $24.92. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -5.03 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The business had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.04 million. During the same quarter in the previous year, the firm posted ($0.87) earnings per share. The company’s revenue was up 95.8% compared to the same quarter last year. As a group, sell-side analysts predict that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on VRDN shares. Wedbush reduced their price objective on Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Stifel Nicolaus set a $39.00 price objective on Viridian Therapeutics in a research note on Wednesday, May 13th. Royal Bank Of Canada boosted their price objective on Viridian Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Wall Street Zen upgraded Viridian Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday. Finally, Truist Financial reduced their price objective on Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $36.14.

Insiders Place Their Bets

In other news, Director Fairmount Funds Management Llc acquired 1,176,470 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the completion of the acquisition, the director directly owned 5,090,928 shares in the company, valued at $86,545,776. This represents a 30.05% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.40% of the stock is currently owned by corporate insiders.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.